Development of an Interleukin-11 Signalling Antagonist

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1147621

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Interleukin (IL)-11 is a soluble signalling molecule that is associated with many types of cancer. We have recently discovered that IL-11 signalling is a novel and tractable therapeutic target for the treatment of colon cancer. The aims of this proposal are to understand the structural details of IL-11 signalling. We will use this information to develop new and improved therapeutics for colon cancer.

Funded Activity Details

Start Date: 01-01-2018

End Date: 01-01-2020

Funding Scheme: Project Grants

Funding Amount: $625,830.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Structural Biology (incl. Macromolecular Modelling)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

cancer treatment | cytokines | interleukins (IL) | receptor binding | structural biology

Related Links